Ladenburg Thalmann Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
More News related to OPTR
- Oppenheimer Upgrades Optimer Pharmaceuticals (OPTR) to Outperform
- Morning Movers 11/12: NLST, HPJ, COMS, AMD, CAAS Higher; TRMS, NWPX, ATRN, BRCD, CDTI, GMCR Lower
- Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection
- Ladenburg Thalmann Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
- Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform
More News related to Downgrades
- Moody's Downgrades Sprint Nextel's (S) Corporate Family Rating; Outlook Negative
- Comverge (COMV) Continuing Lower as Ardour Analyst Cuts to Hold
- Scotia Capital Downgrades New Gold Inc. (NGD) to Sector Underperform
- Craig-Hallum Downgrades ADC Telecom (ADCT) to Accumulate
- Wedbush Downgrades VeriSign (VRSN) to Neutral; Growth Catalysts Not Expected Until 2011
Ladenburg Thalmann downgrades Optimer Pharmaceuticals (Nasdaq: OPTR) from Buy to Neutral. Price target lowered from $17 to $13.50.
To see more analyst ratings on OPTR Click Here.
Related Categories
DowngradesStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
